Functional beverage development from traditional Thai polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment Authors: Thammarat Kaewmanee, Acharaporn Issuriya, Piyapong Choochana, Pinanong Na-Phatthalung, Surasak Limsuwan, Sasitorn Chusri, Shengqian Sun, Shengqian Sun, Shengqian Sun, Shengqian Sun Published: 2025 ABSTRACT This study aimed to optimize microencapsulation conditions for Phy-Blica-O (PBO), a traditional Thai polyherbal tonic, and to assess the safety of its consumer-accepted herbal tea formulation, Phy-Blica-D (PBD). PBO decoction and its phenolic-rich extract were spray-dried at different inlet temperatures (140°C, 180°C) and maltodextrin-gum Arabic ratios. Encapsulation efficiency was highest at 140°C with maltodextrin alone, while antioxidant activity was greatest in microcapsules prepared at 180°C with a 6:4 maltodextrin to gum Arabic ratio, as shown by DPPH, ABTS, and FRAP assays. PBD demonstrated strong in vitro antioxidant activities and was subsequently assessed in a 90-day subchronic toxicity study in Wistar rats. No treatment-related mortality, clinical abnormalities, organ toxicity, or hematological or biochemical disruptions were seen at doses up to 300 mg/kg/day, indicating a NOAEL above this level. These findings suggest that optimized PBO microcapsules and the PBD tea blend are safe, antioxidant-rich functional ingredients with strong potential for commercialization in complementary and integrative medicine. 1. Introduction Functional foods have gained increasing global interest due to their potential role in disease prevention, promoting overall health, and enhancing well-being. Complementary and integrative medicine has extensively employed traditional herbal formulations, particularly polyherbal preparations, to enhance overall health and well-being, including traditional herbal beverages [1]. Herbal beverages are a key part of functional foods and are known for their health benefits, such as boosting energy, alleviating fatigue and stress, enhancing immune function, and offering protection against several metabolic syndromes and age-related diseases [2–4]. The documentation of traditional knowledge combined with the scientific validation of health claims for these beverages is becoming crucial for fostering innovation and gaining consumer acceptance in this market. Our prior research on traditional Thai polyherbal infusions utilized as rejuvenating formulations has identified several promising combinations that exhibit beneficial biological activities related to health, including antioxidant properties and a preventive effect against hyperlipidemia [5–8]. Among these formulas, Phyllanthus emblica-based functional herbal tea (THP-R016 or Phy-Blica-O (PBO)) possessed notable antioxidant properties and did not exhibit cytotoxic effects on Vero cells at concentrations up to 100 µg/mL, supporting its safety for oral applications [9,10]. Numerous studies have confirmed the pharmacological properties of various herbal constituents of PBO in vivo, demonstrating their value in functional foods [9]. However, Allium sativum and Tinospora crispa, which are present in PBO, impart a strong bitter taste and unpleasant odor, limiting their application in the functional food industry. The utilization of microencapsulation in PBO not only enhances the sensory profile but also protects heat-sensitive bioactive compounds from degradation, thereby improving the functional properties and shelf-life of the formulation [11]. Spray-drying was chosen due to its scalability, reduced operational costs, brief processing duration, and appropriateness for heat-sensitive herbal extracts when compared to other methods [11]. Additionally, maltodextrin (MD) and gum Arabic (GA) are common wall materials in spray-drying botanical extracts because of their excellent film-forming, emulsifying, and protective qualities [12–14]. MD helps achieve high encapsulation efficiency and maintains low viscosity, whereas GA improves stability and retains antioxidants. Using them together has been demonstrated to increase encapsulation yields and functional performance in earlier research [12–14]. Phy‑Blica‑D (PBD), an herbal tea blend based on PBO, has been developed with remarkable consumer acceptability and demonstrates gastroprotective effects with an oral no-observed-adverse-effect level exceeding 300 mg/kg body weight/day in the 28-day repeated oral dose toxicity test [15,16]. The calculated human equivalent dose value is 48.39 mg/kg/day, or around 600 mL/kg body weight/day, with no target organs being affected. Nonetheless, regulatory authorities require comprehensive safety evaluations, including sub-chronic oral toxicity studies, to ensure the safety of innovative functional foods meant for regular human intake. The 90-day repeated-dose toxicity test plays a crucial role in detecting possible chronic toxic effects, establishing safe dosage levels (NOAEL), and verifying the absence of target organ toxicity and biochemical irregularities. To facilitate the ongoing advancement of PBO and PBD as herbal-based functional beverages rich in antioxidants, we developed a novel approach by transforming PBO into a functional ingredient using optimized microencapsulation techniques. The conditions for encapsulation, including inlet temperature and wall material composition, were methodically adjusted to improve physicochemical stability and antioxidant effectiveness. This process could enhance the antioxidant properties of PBO and potentially increase consumer acceptance. Additionally, a consumer-acceptable herbal tea blend, PBD, was developed and tested for its antioxidant potential through a series of in vitro assays. Notably, a comprehensive 90-day sub-chronic oral toxicity study in rats was conducted to establish the safety profile of PBD. To our knowledge, this is the first study to combine spray-drying optimization, sensory evaluation, and long-term toxicity assessment for a Thai polyherbal beverage. These findings highlight the potential of PBD as a scientifically validated, antioxidant-rich, and safe functional beverage for commercialization in the complementary and integrative medicine sector. 2. Materials and methods 2.1. Preparation of Phyllanthus emblica-based functional herbal tea The medicinal plants for the herbal tea (see S1 Table) were sourced from licensed supplier Triburi Orsot in Songkhla, Thailand. Each specimen was authenticated by Assistant Professor Dr. Katesarin Maneenoon, a botanist from Prince of Songkla University, using reference samples from the Materia Medica collection. The tea formulations were prepared at the Traditional Thai Medicine Hospital in Hat Yai, Thailand. After cleaning, drying, and milling, the plant parts were combined to create five distinct formulations. Portions of 2.5 g each were packaged in rectangular tea bags (5 × 8 cm2) and stored in sterilized amber glass containers at room temperature until use. To prepare tea infusions, each tea bag was steeped in 120 mL of freshly boiled water (98 ± 2°C) and brewed for precisely 3 minutes without agitation [16]. Sensory evaluation of the herbal tea was performed by a trained panel of 30 individuals at the Department of Food Sciences and Nutrition, Prince of Songkla University. The sensory assessment included parameters such as color, aroma, taste, and overall acceptability, rated on a 9-point hedonic scale ranging from 1 (extremely disliked) to 9 (extremely liked) [16]. 2.2. Development of microcapsules containing PBO decoction and its phenolic-rich extract Tea infusions, prepared as mentioned above, were freeze-dried (U535-86, New Brunswick, UK), with extraction yields calculated for each formulation. The extracts obtained were stored in sterilized amber tubes at −20°C for up to three days prior to preparation for analysis (Fig 1). Schematic workflow illustrating the preparation of Phy-Blica-O decoction (Section 2.1), extraction of its phenolic-rich extract (Section 2.2), and development of its microencapsulation using spray drying (Section 2.3). The process starts with preparing PBO decoction, followed by freeze-drying to produce powdered extract. The phenolic-rich extract is then obtained through a series of solvent partitioning steps involving diethyl ether, chloroform, and ethyl acetate under pH-controlled conditions (upper panel). Both the PBO decoction and its phenolic-rich extract are used as core materials for microencapsulation. Coating materials, including maltodextrin (MD) and gum Arabic (GA), are dissolved in water and mixed with the core materials at different ratios. The feed slurry is spray-dried at inlet temperatures of 140°C and 180°C to produce encapsulated powders, which are then evaluated for their physicochemical and antioxidant properties (lower panel). The stepwise solvent extraction method employed here follows established protocols for phenolic isolation [20,21], where initial basification (pH 8–10) enhances solubility of non-phenolics, while subsequent acidification (pH 3–4) facilitates phenolic partitioning into ethyl acetate. This approach was validated in prior studies [17,18] for optimizing polyphenol yield from botanical extracts. An aliquot (1 mL) of the PBO solution (0.2 g/mL in DMSO) was diluted with water to 20 μg/mL and mixed with 50 mL of diethyl ether in a separatory funnel. The diethyl ether fraction was collected, while the aqueous fraction was retained. The pH of the aqueous portion was adjusted to 8–10 with 20 g/100 mL NaHCO3 and extracted with 50 mL of chloroform to obtain the nonphenolic fraction. This aqueous fraction was mixed with 6 mol/L HCl to adjust the pH to 3–4 and then partitioned with 50 mL of ethyl acetate. The ethyl acetate layer and the aqueous portion yielded the polyphenolic and residual fractions, respectively (Fig 1). Each partitioning process was conducted twice, with the solvents subsequently evaporated using a rotary evaporator (EZ-2 Series, Genevac Ltd., United Kingdom). The powdered samples were then stored in airtight containers at −20 °C for future use. 2.3. Preparation of microcapsules from PBO decoction and its phenolic-rich extract Microencapsulation of PBO decoction and its phenolic-rich extract was conducted using a laboratory-scale spray dryer (Buchi Mini Spray Dryer B-290, Switzerland) with a 0.7 mm nozzle aperture, as summarized in Fig 1, lower panel. Each coating material was prepared by dispersing maltodextrin (MD) and gum Arabic (GA) in the desired ratio in distilled water at a 1:5 (w/w) ratio. The mixture was allowed to swell overnight, while magnetic stirring was employed to ensure thorough dissolution before the spray drying process. The feed solution was prepared by infusing 450 mL of either PBO or its phenolic-rich extract at concentrations of 1% and 10% (w/v) in 95% food-grade ethanol with the mixture of MD: GA solution through vigorous magnetic stirring at a 1:1 ratio. The feeding solutions were archived with different core-to-coating material ratios of 1:2 and 1:20 [17–19]. A total volume of 100 mL of solution was homogenized at 13500 rpm for 3 minutes using an Ultra-Turrax apparatus (IKA-Werke GmbH & Co. KG, Staufen, Germany). Soluble solid concentrations were measured at 20.4–21.0 °Brix for the feed solution and 8.1–9.6 °Brix for maltodextrin. The slurry was introduced into the main chamber via a peristaltic pump at a feed flow rate of about 10 mL/min (15 rpm). Compressor pressure ranged from 4.8–6.4 kg/cm2, with an aspirator rate of 100%. Inlet air temperatures were set at 140 and 180 °C, which were chosen based on previous studies on spray-drying of herbal extracts [13,17,18], with outlet temperatures recorded for each sample. The drying procedure was performed in triplicate. The resulting powder was collected from the cyclone chamber and stored at 4 °C in a sealed amber bottle. The weights of the microencapsulated powders were recorded, and yield efficiencies were calculated as the ratio of the total solids in the powder to those in the feed mixture. 2.4. Physicochemical characters of encapsulated powders The physicochemical characteristics of encapsulated powders of PBO decoction and its phenolic-rich extract were evaluated through a series of analyses, as previously outlined in an earlier publication [17,18]. Particle size distribution and mean particle size were assessed in triplicate with a Malvern Scirocco 2000 particle analyzer (Malvern Instruments, Worcestershire, U.K.) utilizing isopropanol for dispersion. Morphological characteristics, such as surface appearance and particle size, were analyzed using scanning electron microscopy (SEM; SEMJSM5800LV model, Japan), with gold-coated samples examined at a magnification of 5000× under a 30 kV accelerating voltage. Tap density was derived by placing 2 g of powder into a 10 mL graduated cylinder and tapping until a constant volume was reached, with density calculated as the mass-to-volume ratio. Hygroscopicity was evaluated by measuring mass changes after 24 hours and 7 days of exposure to controlled humidity conditions (76.5–78% RH). Color properties (L*, a*, b*) were recorded using a calibrated Hunter Lab Color Quest XE colorimeter (Mini Scan X.E., Model 45/0S, Hunter Associates Laboratory Inc., USA), with measurements taken in triplicate. Moisture content was obtained through oven drying at 105°C until a consistent weight was achieved, while water activity was assessed at equilibrium using an Aqua Lab analyzer (Aqua Lab, Series 3 C.E., USA) at 25°C. 2.5. Antioxidant capacities of encapsulated powders and Phyllanthus emblica-based functional herbal tea Encapsulated powders from PBO decoction and its phenolic-rich extract, created using different inlet temperatures and various wall material ratios, were evaluated and compared for their in vitro antioxidant capacities. Their radical scavenging abilities were evaluated using modified DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS (2,20-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid) assays. Encapsulated powders were initially dissolved in 50% dimethyl sulfoxide (DMSO), followed by serial two-fold dilutions to produce a concentration series from 2500 to 1.22 µg/mL. Trolox, which serves as a standard antioxidant, was also diluted (1250–0.61 µg/mL). The superoxide radical scavenging activity of each microcapsule powder was assessed using a modified nitroblue tetrazolium (NBT) reduction method. In this procedure, superoxide radicals generated by a riboflavin/methionine/illumination reaction convert NBT into purple formazan, which is quantified using a spectrophotometer. Specifically, reaction mixtures of riboflavin, methionine, EDTA, and a range of extract concentrations (156.25–4.88 μg/mL in phosphate buffer, pH 7.4) were combined with NBT solution and exposed to fluorescent light (20 W) at 25°C for 25 minutes. The absorbance of the resulting formazan dye was measured at 560 nm, with catechin being used as the reference antioxidant. Free radical inhibition was reported in terms of IC50 (mg/mL), which represents the concentration needed to achieve 50% radical inhibition, as described by previous methods [7,9,10]. The FRAP assay was employed to measure the reducing capability of the powders. A 30 µL sample was combined with 270 µL freshly prepared FRAP reagent, and absorbance changes were recorded at 596 nm after 30 minutes of incubation. Results were expressed as millimolar equivalents of FeSO4 per gram extract, determined using a standard FeSO4 calibration curve. Total phenolic content was measured using the Folin-Ciocalteu method. Fifteen µL of extracts (2.5 mg/mL) reacted with 125 µL of Folin-Ciocalteu reagent for 5 minutes, then 125 µL of sodium carbonate (20% w/v) was added. After incubating in darkness for one hour, absorbance at 725 nm was recorded. TPC values were based on a gallic acid standard curve and expressed as mg GAE per gram of extract [7,9]. In addition, Phyllanthus emblica-based functional herbal tea decoction, as previously described, was freeze-dried, with extraction yields calculated for each formulation. Extracts obtained were stored in sterilized amber tubes at −20°C for up to three days prior to analysis. The scavenging activities against superoxide anion and peroxyl radicals were measured using NBT and the ORAC assays [7]. The lipid peroxidation inhibitory capacities of the extracts were evaluated with slight modifications to a previously established method [20]. Specifically, varying concentrations (0.1–1 mg/mL) of each extract were prepared. Ten microliters of each concentration were added to a glass tube containing 12.5 mg/mL egg yolk (50 µL), 20% acetic acid (150 µL), 0.8% TBA (150 µL), and 40 µL distilled water. The mixture was vortexed for 10 seconds and heated at 95 °C for one hour. Absorbance (532 nm) of the resulting solution was measured against a blank without egg yolk, using butylated hydroxytoluene (BHT) as a positive control. 2.6. Sub-chronic oral toxicity study Healthy adult male Wistar rats (300–350 g) and female Wistar rats (200–250 g) were obtained from the National Laboratory Animal Center in Thailand. The animals were housed individually in a controlled environment with temperatures maintained between 23 and 25°C, humidity levels of 50–55%, and a 12-hour light-dark cycle. They were given sterilized feed and purified water ad libitum. The study followed OECD Guideline 408 [21–23] and received approval from the Animal Ethical Committee at Prince of Songkla University 0521.11/711). After a two-week acclimatization, rats were randomly assigned to four groups (n = 10 males, n = 10 females per group), maintaining weight variations within ±5% between groups. The control group received distilled water orally, while the experimental groups received daily doses of Phy-Blica-D extracts at 5, 50, and 300 mg/kg body weight for 90 days. Humane endpoints were established before the study. Animals were monitored twice daily for pain, distress, infection, or adverse reactions. Humane euthanasia criteria included persistent weight loss (>20%), decreased mobility, excessive grooming or vocalization, abnormal posture, and lack of response to stimuli. Animals showing these signs were euthanized immediately with sodium pentobarbital (≥150 mg/kg, intraperitoneal). No unexpected mortalities occurred; all animals survived until their endpoints. Animals were monitored daily for mortality, clinical symptoms, behavioral changes, signs of pain, distress, or abnormal behavior. Any animals showing signs of suffering were evaluated by a veterinarian for early humane euthanasia if necessary. Body weight and food consumption were logged daily. On the 90th day, the animals were anesthetized under deep anesthesia using an intraperitoneal injection of sodium pentobarbital (60 mg/kg), and blood samples were drawn for hematological and biochemical analyses. Additionally, organ weights were recorded, and standard histological procedures were used to conduct histopathological examinations of the liver, kidneys, lungs, and spleen. 2.7. Statistical analysis Data is shown as mean ± standard error or mean ± standard deviation. Antioxidant capacity, body weights, food intake, relative organ weights, and both hematological and biochemical parameters were all assumed to follow a normal distribution. Sensory scores and group differences were examined using one-way ANOVA with Bonferroni’s post-hoc tests, conducted via the Statistical Package for the Social Sciences (SPSS 19) on Windows. A P-value of less than 0.05 was deemed statistically significant. 3. Results 3.1. Microencapsulation conditions and efficiency The selection of coating materials and the specifications regarding inlet temperatures were derived from prior research that developed and employed herbal-based microcapsules as functional ingredients for food and beverage applications. These microcapsules consist of either a crude decoction of PBO or its phenolic-rich extract as core materials. The decoction of PBO, consisting of 11 medicinal plants (S1 Table), was prepared using boiling water, following the traditional method detailed previously. The yield of this decoction was found to be 14.56% (w/w), while the phenolic-rich extract (PRF) was produced subsequently with a yield of 9.59% (w/w). Table 1 displays the yields and efficiencies of encapsulation for crude and its PRF at different inlet temperatures (140°C, 180°C) and varying ratios of coating materials (maltodextrin [MD]: gum Arabic [GA]). Both crude extract (1:2 core-to-coating ratio, w/w) and the PRF (1:20 core-to-coating ratio, w/w) were assessed to determine optimal encapsulation parameters. 10.1371/journal.pone.0339571.t001Table 1Encapsulation conditions, yields, and efficiency of Phy-Blica-O particles prepared at various inlet temperatures and different proportions of wall materials.Core material(Core: Coating material)Codes of samplesInlet temp. (°C)Coating material (MD: GA)Yield (%)Microcapsule efficiency (%)Crude extract (1:2; w/w)CE140_10:014010:067.4794.03 ± 0.52aCE140_8:21408:274.6986.45 ± 0.50cCE140_6:41406:470.7175.90 ± 0.07eCE180_10:018010:069.4189.72 ± 0.88bCE180_8:21808:270.8584.44 ± 1.46dCE180_6:41806:475.0084.37 ± 0.33dPhenolic rich fraction (1:20; w/w)PRF140_10:014010:067.3296.29 ± 0.35aPRF140_8:21408:277.2370.96 ± 0.30ePRF140_6:41406:472.3977.98 ± 1.20cPRF180_10:018010:071.2983.55 ± 0.10bPRF180_8:21808:270.6373.58 ± 0.66dPRF180_6:41806:470.9170.68 ± 0.51ea–e Values are presented as mean ± SD. Means within a column for each sample sharing a common superscript letter are not significantly different (p < 0.05) as analyzed by one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. MD; maltodextrin: GA; gum Arabic. The effect size (η2) for microcapsule efficiency, with 95% confidence intervals, is 0.995 (0.80–0.82). Encapsulation conditions, yields, and efficiency of Phy-Blica-O particles prepared at various inlet temperatures and different proportions of wall materials. a–e Values are presented as mean ± SD. Means within a column for each sample sharing a common superscript letter are not significantly different (p < 0.05) as analyzed by one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. MD; maltodextrin: GA; gum Arabic. The effect size (η2) for microcapsule efficiency, with 95% confidence intervals, is 0.995 (0.80–0.82). The encapsulation yield for the crude extract varied between 67.47% and 75.00%, peaking at 75.00% with an inlet temperature of 180°C and a MD:GA ratio of 6:4 (CE180_6:4). In contrast, the highest encapsulation efficiency for crude extracts was recorded at 140°C with only MD, reaching 94.03% (CE140_10:0). The lowest efficiency (75.90%) occurred at the same temperature with an MD:GA ratio of 6:4 (CE140_6:4). This clearly demonstrates that a higher MD proportion at lower temperatures improved encapsulation efficiency. In a similar manner, the yields for the PRF ranged from 67.32% to 77.23%. The peak yield of 77.23% was obtained at 140°C with an MD to GA ratio of 8:2 (PRF140_8:2). Interestingly, the highest encapsulation efficiency for the PRF was found to be 96.29% at 140°C when using MD exclusively (PRF140_10:0), while the lowest efficiency of 70.68% occurred at 180°C with an MD:GA ratio of 6:4 (PRF180_6:4). It is observed that a higher MD proportion (10:0) at 140°C achieves the best encapsulation efficiency (94.03% for crude extract; 96.29% for PRF), despite slightly lower results than other conditions. Additionally, increasing GA reduces microencapsulation efficiency, indicating that maltodextrin alone better preserves bioactive components during encapsulation. 3.2. Physicochemical properties of microencapsulated PBO The physicochemical characterization of microencapsulated Phy-Blica-O powders is detailed in Table 2. It indicates the variation in particle size, bulk and tap densities, moisture content, water activity, and hygroscopicity under different encapsulation conditions. Powders encapsulated at higher inlet temperatures (180°C) showed lower moisture content and water activity but increased hygroscopicity. The smallest particle sizes and higher hygroscopicity after 7 days were notably observed with higher GA proportions, indicating potential moisture absorption issues affecting storage stability. 10.1371/journal.pone.0339571.t002Table 2The physicochemical properties of microencapsulated Phy-Blica-O produced at different inlet temperatures and with varying proportions of wall materials.SamplesAverage particle size (µm) (Range)Bulk density (Kg/m2)Tap density (Kg/m2)Moisture content (%)Water activity (%)Hygroscopicity (%)24 hours7 daysCE140_10:06.67 ± 4.03 (0.26-22.73)0.23 ± 0.00b0.39 + 0.00d6.26 ± 0.03c0.35 ± 0.00b10.32 ± 0.07d11.22 ± 0.08eCE140_8:27.92 ± 5.80 (0.21-76.42)0.23 ± 0.00b0.39 ± 0.01c,d7.11 ± 0.02a0.37 ± 0.00a12.27 ± 0.07c12.99 ± 0.06dCE140_6:46.01 ± 3.74 (0.21-22.73)0.25 ± 0.00a0.39 ± 0.00b,c,d6.47 ± 0.03b0.33 ± 0.00c10.10 ± 0.06e11.02 ± 0.05fCE180_10:06.78 ± 4.16 (0.26-24.95)0.21 ± 0.00d0.40 ± 0.00b,c4.51 ± 0.15e0.25 ± 0.00e12.83 ± 0.06b13.89 ± 0.06bCE180_8:26.93 ± 4.28 (0.24-27.39)0.23 ± 0.00b0.40 ± 0.00b5.03 ± 0.09d0.26 ± 0.00d12.34 ± 0.07c13.10 ± 0.05cCE180_6:46.34 ± 4.06 (0.24-43.67)0.22 ± 0.00c0.45 ± 0.01a4.96 ± 0.08d0.23 ± 0.00f14.29 ± 0.07a15.51 ± 0.08aPRF140_10:08.54 ± 5.88 (0.26-63.41)0.22 ± 0.00b0.35 ± 0.01e5.44 ± 0.01b0.34 ± 0.00b10.21 ± 0.02f10.70 ± 0.02fPRF140_8:27.36 ± 4.21 (0.16-24.95)0.22 ± 0.00b0.39 ± 0.01c5.28 ± 0.06c0.31 ± 0.00c11.53 ± 0.07c11.95 ± 0.06cPRF140_6:47.86 ± 4.50 (0.16-30.07)0.20 ± 0.00c0.41 ± 0.01b6.38 ± 0.02a0.37 ± 0.00a12.23 ± 0.03b12.51 ± 0.07bPRF180_10:08.08 ± 4.82 (0.21-30.07)0.22 ± 0.00b0.36 ± 0.01d4.85 ± 0.04d0.30 ± 0.00d11.27 ± 0.08d11.56 ± 0.07dPRF180_8:26.79 ± 3.76 (0.13-22.73)0.20 ± 0.00c0.41 ± 0.00b4.21 ± 0.01e0.24 ± 0.00f11.05 ± 0.08e11.10 ± 0.09ePRF180_6:46.89 ± 3.68 (0.18-20.71)0.24 ± 0.00a0.44 ± 0.01a4.89 ± 0.07d0.26 ± 0.00e12.59 ± 0.03a12.95 ± 0.03aa–f Values are presented as mean ± SD. Means within each column that share the same superscript letter indicate no significant difference (p < 0.05), determined by one-way ANOVA followed by Bonferroni’s post-hoc tests. The effect size (η2) for moisture content, water activity, and hygroscopicity at 7 days, with 95% confidence intervals, is 0.946 (0.84–0.97), 0.940 (0.82–0.96), and 0.859 (0.70–0.93), respectively. The physicochemical properties of microencapsulated Phy-Blica-O produced at different inlet temperatures and with varying proportions of wall materials. a–f Values are presented as mean ± SD. Means within each column that share the same superscript letter indicate no significant difference (p < 0.05), determined by one-way ANOVA followed by Bonferroni’s post-hoc tests. The effect size (η2) for moisture content, water activity, and hygroscopicity at 7 days, with 95% confidence intervals, is 0.946 (0.84–0.97), 0.940 (0.82–0.96), and 0.859 (0.70–0.93), respectively. The average particle size of the microcapsules varied from 6.01 to 8.54 µm, exhibiting broad particle-size distributions ranging from as small as 0.13 µm to as large as 76.42 µm (see S1 and S2 Figs). The bulk density values ranged from 0.20 to 0.25 kg/m2, while tap densities spanned 0.35 to 0.45 kg/m2. This indicates moderate variability among formulations, which could affect handling and storage. Moisture content was notably affected by drying conditions, showing lower moisture levels (4.21%) at elevated temperatures (180°C, PRF180_8:2), whereas lower temperatures resulted in higher moisture content (up to 7.11%, CE140_8:2). Water activity also fluctuated, with higher activity (up to 0.37, CE140_8:2 and PRF140_6:4) linked to the lower drying temperatures. Hygroscopicity tests revealed greater moisture absorption during storage. Formulations with higher gum arabic ratios, especially CE180_6:4, exhibited the highest hygroscopicity (15.51% after 7 days), indicating potential concerns regarding storage and stability in humid environments. Effect sizes (η2) and 95% confidence intervals (CI) were calculated to complement p-values and quantify the magnitude of treatment effects. Microencapsulation efficiency demonstrated an extremely large effect (η2 = 0.995, 95% CI: 0.80–0.82). Significant differences in physicochemical properties were also associated with large effect sizes, including moisture content (η2 = 0.946, 95% CI: 0.84–0.97), water activity (η2 = 0.940, 95% CI: 0.82–0.96), and hygroscopicity after 7 days (η2 = 0.859, 95% CI: 0.70–0.93). These results indicate that inlet temperature and wall-material ratios have strong practical effects on powder characteristics. Overall, these physicochemical evaluations underscore the significant effects of drying temperatures and wall material compositions on the characteristics of microcapsules, highlighting the need for optimized parameters to enhance the stability and quality of functional microencapsulated products. 3.3. Appearance and color parameters of microencapsulated PBO powders Color properties (Table 3), measured as L* (lightness), a* (redness-greenness), b* (yellowness-blueness), Delta E (color difference), and whiteness values, are crucial for determining consumer acceptance and market potential of functional powders. Typically, a rise in GA proportion led to a decrease in whiteness and an increase in yellowness (higher b* values), which could impact visual acceptability. Additionally, phenolic-rich fractions encapsulated at elevated temperatures showed enhanced whiteness, hinting at a potential benefit for consumer preference when choosing encapsulation conditions. Microcapsules produced through spray drying presented spherical forms with varying surface indentations and particle integrity, influenced by the inlet temperatures (140°C and 180°C) and the MD to GA ratio (Figs 2 and 3). At both temperatures, microcapsules made solely with MD exhibited relatively consistent spherical shapes with minor surface indentations, indicating satisfactory encapsulation integrity. An increase in the GA proportion led to microcapsules featuring more pronounced dents, irregular surfaces, and greater size variability, especially notable at the 6:4 MD:GA ratio. Furthermore, samples dried at the higher temperature of 180°C appeared smoother and more compact compared to those dried at 140°C, suggesting enhanced structural stability and possible benefits for the product’s shelf-life. These findings emphasize the crucial role of formulation parameters in determining the physical quality and integrity of microencapsulated powders. 10.1371/journal.pone.0339571.t003Table 3The appearance of microencapsulated Phy-Blica-O powders varies based on different inlet temperatures and wall material proportions.CodesL*a*b*Delta EWhiteness valueCE140_10:080.04 ± 1.02b1.74 ± 0.10a19.17 ± 0.63a24.03 ± 1.06b72.27 ± 1.10bCE140_8:282.08 ± 1.07a1.15 ± 0.07c17.91 ± 0.52d21.76 ± 1.06c74.64 ± 1.12aCE140_6:478.45 ± 0.77c1.68 ± 0.09b19.34 ± 0.34a25.19 ± 0.68a70.99 ± 0.72cCE180_10:080.19 ± 1.24b1.65 ± 0.10b18.21 ± 0.54c23.20 ± 1.11c73.03 ± 1.18bCE180_8:281.51 ± 2.16a1.15 ± 0.06c17.52 ± 0.59e21.83 ± 1.78c74.48 ± 1.91aCE180_6:478.48 ± 1.14c1.72 ± 0.12a18.75 ± 0.56b24.74 ± 1.01a,b71.40 ± 1.06cPRF140_10:089.24 ± 1.54c,d0.16 ± 0.03c9.83 ± 0.24b11.07 ± 1.00a85.39 ± 1.23cPRF140_8:288.97 ± 1.26c,d0.44 ± 0.04a10.02 ± 0.48b11.35 ± 1.06a85.08 ± 1.23cPRF140_6:489.67 ± 1.41c0.15 ± 0.05c10.28 ± 0.43a11.23 ± 0.94a85.40 ± 1.18cPRF180_10:090.43 ± 0.95b0.24 ± 0.03b8.96 ± 0.32d9.68 ± 0.68b86.88 ± 0.87bPRF180_8:291.59 ± 1.19a0.09 ± 0.03d8.41 ± 0.36e8.70 ± 0.73c88.09 ± 1.02aPRF180_6:489.14 ± 1.07c,e0.15 ± 0.04c9.42 ± 0.40c10.75 ± 0.80a85.61 ± 0.95ca–e Values are expressed as mean ± SD (n = 9). Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. The appearance of microencapsulated Phy-Blica-O powders varies based on different inlet temperatures and wall material proportions. a–e Values are expressed as mean ± SD (n = 9). Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Scanning electron micrographs depict the morphology of microencapsulated Phy-Blica-O powders created through spray drying at inlet temperatures of 140°C (A–C) and 180°C (D–F). The powders utilize different maltodextrin (MD) to gum Arabic (GA) ratios: (A, D) MD:GA (10:0), (B, E) MD:GA (8:2), and (C, F) MD:GA (6:4). The scale bars indicate 5 µm with a magnification of ×5000. Scanning electron micrographs depict the morphology of microencapsulated phenolic-rich fraction of Phy-Blica-O powders created through spray drying at inlet temperatures of 140°C (A–C) and 180°C (D–F). The powders utilize different maltodextrin (MD) to gum Arabic (GA) ratios: (A, D) MD:GA (10:0), (B, E) MD:GA (8:2), and (C, F) MD:GA (6:4). The scale bars indicate 5 µm with a magnification of ×5000. 3.4. Antioxidant properties of microencapsulated PBO powders The antioxidant evaluations presented in Table 4 reveal differences in antioxidant strength depending on encapsulation conditions. Microcapsules containing higher proportions of GA (CE140_6:4 and CE180_6:4) exhibited significantly elevated total phenolic content and strong antioxidant activity, as evidenced by the lowest IC50 values in the ABTS assay, highlighting the protective influence of GA on phenolic compounds. The phenolic-rich fractions displayed significantly lower antioxidant activities due to the reduced amounts of core material used in the preparation of microcapsules. This suggests that crude extracts could be suitable for creating microcapsules with higher antioxidant strength. The total phenolic content in crude extracts ranged from 85.88 to 102.05 mg GA/g extract, which is notably higher than that in phenolic-rich fractions (10.55 to 17.77 mg GA/g extract). Among these crude extracts, CE140_6:4 had the highest total phenolic content (102.05 mg GA/g extract), closely followed by CE180_6:4 (101.71 mg GA/g extract). In radical scavenging assays, crude extracts demonstrated strong antioxidant activity, indicated by lower IC₅₀ values, particularly CE140_10:0 and CE180_6:4 in both the ABTS (0.156 and 0.095 mg/mL, respectively) and DPPH assays. Consistently, the FRAP assay, which measures reducing power, also showed superior activity for CE180_6:4 (4.15 mM Fe₂SO₄/mg). 10.1371/journal.pone.0339571.t004Table 4The antioxidant properties of microencapsulated Phy-Blica-O and its phenolic-rich fraction, produced with varying inlet temperatures and different proportions of wall materials.CodesTotal phenolic content mg GA/g extractDPPH (IC50) mg/mLABTS (IC50) mg/mLFRAP mM Fe2SO4/mgNBT (IC50) mg/mLCE140_10:087.64 ± 2.77c0.311 ± 0.003d0.156 ± 0.004d3.55 ± 0.04c0.29 ± 0.00aCE140_8:285.88 ± 1.54c0.409 ± 0.006b0.258 ± 0.001e3.62 ± 0.03c0.38 ± 0.02bCE140_6:4102.05 ± 3.30a0.375 ± 0.016c0.109 ± 0.003b3.82 ± 0.01b0.51 ± 0.03dCE180_10:087.44 ± 2.88c0.515 ± 0.005a0.162 ± 0.003d3.76 ± 0.02b0.29 ± 0.01aCE180_8:293.25 ± 2.13b0.422 ± 0.004b0.129 ± 0.005c4.10 ± 0.02a0.37 ± 0.01bCE180_6:4101.71 ± 3.25a0.378 ± 0.017c0.095 ± 0.003a4.15 ± 0.08a0.41 ± 0.01cPRF140_10:014.62 ± 0.87c1.238 ± 0.015e1.323 ± 0.007c0.42 ± 0.01d1.58 ± 0.06bPRF140_8:210.88 ± 0.45e2.211 ± 0.004b1.536 ± 0.003d0.39 ± 0.01e1.46 ± 0.04aPRF140_6:416.82 ± 0.62b2.704 ± 0.009a1.106 ± 0.003b0.65 ± 0.02b1.68 ± 0.04cPRF140_10:010.55 ± 0.42e1.974 ± 0.004c1.443 ± 0.004c,d0.50 ± 0.01c2.23 ± 0.10cPRF140_8:212.27 ± 0.71d1.865 ± 0.002d1.359 ± 0.001c0.74 ± 0.00a2.34 ± 0.11cPRF140_6:417.77 ± 0.97a2.717 ± 0.008a1.021 ± 0.002a0.67 ± 0.01b2.64 ± 0.03da–e Values are expressed as mean ± SD. Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. The antioxidant properties of microencapsulated Phy-Blica-O and its phenolic-rich fraction, produced with varying inlet temperatures and different proportions of wall materials. a–e Values are expressed as mean ± SD. Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Although CE140_6:4 exhibited the highest TPC, CE180_6:4 consistently showed superior activity in DPPH, ABTS, and FRAP assays (p < 0.05). This suggests that antioxidant potency may be driven not only by TPC quantity but also by the retention and stability of specific phenolic compounds during high-temperature drying. Collectively, CE180_6:4 consistently showed superior antioxidant performance across multiple antioxidant assays, marking it as the optimal microcapsule formulation for maximizing antioxidant activity. These results emphasize the significant impact of encapsulation conditions and wall material proportions on preserving antioxidant properties, underscoring the ideal conditions for enhancing bioactivity in functional food formulations. 3.5. Radical scavenging capacity and lipid peroxidation inhibition of Phyllanthus emblica-based herbal teas The microcapsules developed demonstrate notable antioxidant properties comparable to those of the PBO decoction. Consequently, both the microcapsule and the decoction can serve as functional beverages. Nonetheless, certain spices and herbs found in PBO, such as Allium sativum and Tinospora crispa, impart a strong bitter taste and unpleasant odor, limiting their application in the functional food industry. To enhance consumer acceptance, we incorporated various edible medicinal plants and spices into the formulation. S2 Table presents the sensory properties of P. emblica-based herbal tea samples made with different medicinal plants. The samples (Phy-Blica-A, Phy-Blica-B, Phy-Blica-C, Phy-Blica-D, and Phy-Blica-E) were sensorially compared to the original tea (PBO). Mean scores for odor, taste, and overall acceptability showed no significant differences among the herbal formulations, except for PBO. It should be noted that among the five formulations tested, Phy-Blica-D (PBD) scored the highest in taste (5.50 ± 0.35; p < 0.05) and overall acceptability (5.60 ± 0.37; p < 0.05), significantly outperforming PBO (2.70 ± 0.34 and 2.90 ± 0.36). The P. emblica-based tea with Aegle marmelos scored higher for taste, appearance, and acceptability. Panelists favored PBD (32.5%) over Phy-Blica-B (30%), Phy-Blica-E (26%), Phy-Blica-C (9%), and Phy-Blica-A (2.5%). Given the consumer acceptability results, Phy-Blica-B, Phy-Blica-D, and Phy-Blica-E were assessed for antioxidant capacity Phy-Blica-O. Table 5 presents the scavenging activity against peroxyl and superoxide anion radicals, along with the inhibitory effects on lipid peroxidation, of four different Phyllanthus emblica-based herbal tea formulations (Phy-Blica-O, B, D, and E). The antioxidant capacities were assessed using peroxyl radical scavenging (expressed as µM Trolox equivalents [TE]/µg extract) and the kinetic inhibition of fluorescence decay in fluorescein (S3 Fig), superoxide anion radical scavenging (IC₅₀), and inhibition of lipid peroxidation (percentage inhibition of MDA). Among the tested herbal teas, PBD exhibited the highest peroxyl radical scavenging activity (10.95 ± 0.12 µM TE/µg), followed by PBO (9.22 ± 0.09 µM TE/µg). For superoxide anion radical scavenging, PBO demonstrated superior activity with the lowest IC₅₀ (47.07 ± 1.84 µg/mL), indicating more substantial scavenging potential compared to other formulations. Similarly, PBO showed a notable inhibitory effect on lipid peroxidation (77.39 ± 6.21% inhibition), markedly higher than other tested herbal teas. 10.1371/journal.pone.0339571.t005Table 5The scavenging capacity of Phyllanthus emblica-based functional herbal tea against peroxyl and superoxide anion radicals and its inhibitory effect on lipid peroxidation.Tested extractsScavenging activity againstMDA inhibition(%; mean±SD)Peroxyl radicalSuperoxide anion radical(µM TE/µg of extract)IC50 (µg/mL)Phy-Blica-O9.22 ± 0.09b47.07 ± 1.84a77.39 ± 6.21aPhy-Blica-B4.89 ± 0.19d128.76 ± 3.24c43.48 ± 1.66bPhy-Blica-D10.95 ± 0.12a82.63 ± 10.08b32.85 ± 21.15cPhy-Blica-E6.42 ± 0.19c94.25 ± 5.46b35.51 ± 0.69cRegarding superoxide anion scavenging, the IC50 value of catechin, a reference antioxidant, was measured at 6.15 ± 0.29. The lipid peroxidation inhibitory effect of Phyllanthus emblica-based functional herbal tea was evaluated at a concentration of 5 µg/mL, and the percentage of malondialdehyde (MDA) for butylated hydroxyanisole, another reference antioxidant, was recorded at 85.05 ± 2.71%. a–c Values are expressed as mean ± SD. Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. The scavenging capacity of Phyllanthus emblica-based functional herbal tea against peroxyl and superoxide anion radicals and its inhibitory effect on lipid peroxidation. Regarding superoxide anion scavenging, the IC50 value of catechin, a reference antioxidant, was measured at 6.15 ± 0.29. The lipid peroxidation inhibitory effect of Phyllanthus emblica-based functional herbal tea was evaluated at a concentration of 5 µg/mL, and the percentage of malondialdehyde (MDA) for butylated hydroxyanisole, another reference antioxidant, was recorded at 85.05 ± 2.71%. a–c Values are expressed as mean ± SD. Means within a column for each sample sharing a different superscript letter indicate a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. 3.6. Sub-chronic oral toxicity assessment A 90-day sub-chronic oral toxicity assessment was conducted on the polyherbal tea PBD, which is recognized for its potent antioxidant properties and significant consumer acceptance, to evaluate its safety and identify potential health risks associated with prolonged usage. In the course of the 90-day repeated oral dose toxicity study, no treatment-related mortality was recorded. Additionally, no behavioral alterations or observable symptoms of toxicity attributed to the administration of PBD were noted in the subjects throughout the treatment duration. During the 90-day study, both male and female rats across all treatment groups exhibited a steady, progressive increase in body weight, aligning with normal growth patterns. No unusual fluctuations, sudden drops, or dose-related deviations were noted compared to the control group. Weekly food intake also remained stable across all groups, with only minor physiological changes from week to week that stayed within expected ranges, showing no signs of treatment-related effects. These consistent trends in body weight and food consumption throughout the study support the conclusion that Phy-Blica-D administration at all tested doses did not produce adverse effects (Fig 4). Changes in body weight (panels A and B) and food consumption (panels C and D) in male and female rats exposed to doses of 5, 50, and 300 mg/kg/day during a 90-day repeated oral dose toxicity study of Phy-Blica-D are presented as mean ± SD (n = 5). * Indicating a significant difference (p < 0.05) among the groups each week, based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. The findings indicate that the repeated oral administration of PBD (5, 50, and 300 mg/kg) did not result in any alterations to the structural morphology of the liver, kidneys, lungs, and spleen in the treated rats when compared to the control group (refer to Table 6). Furthermore, no significant variations in the relative weights of the liver, kidneys, lungs, and spleen were noted among all PBD-dosed rats in comparison to the control rats associated with both sexes. 10.1371/journal.pone.0339571.t006Table 6Relative organ weights of male and female rats administered oral doses of 5, 50, and 300 mg/kg/day of Phy-Blica-D extract during a 90-day repeated oral dose toxicity study.Percentage of relative organ weight (mean±SD)OrgansControlDoses of Phy-Blica-D extract (mg/kg/day)550300Male Liver2.987 ± 0.1553.032 ± 0.2382.954 ± 0.2072.927 ± 0.105 Spleen0.196 ± 0.0220.193 ± 0.0130.181 ± 0.0170.186 ± 0.011 Kidney0.521 ± 0.0210.533 ± 0.0230.501 ± 0.0480.518 ± 0.020 Lung0.355 ± 0.0260.349 ± 0.0150.348 ± 0.0190.355 ± 0.017Female Liver2.893 ± 0.1772.936 ± 0.2912.914 ± 0.2712.794 ± 0.256 Spleen0.246 ± 0.0110.244 ± 0.0330.229 ± 0.0250.236 ± 0.036 Kidney0.561 ± 0.0250.578 ± 0.0240.546 ± 0.0400.552 ± 0.023 Lung0.439 ± 0.0370.417 ± 0.0200.448 ± 0.0180.419 ± 0.035Values are expressed as mean ± SD. * Within a row for each organ, indicates a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Relative organ weights of male and female rats administered oral doses of 5, 50, and 300 mg/kg/day of Phy-Blica-D extract during a 90-day repeated oral dose toxicity study. Values are expressed as mean ± SD. * Within a row for each organ, indicates a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. As illustrated in Table 7, the statistical analysis of hematological parameters reveals no significant differences between the treated and control groups across both genders at the conclusion of the treatment period. Additionally, Fig 5 further demonstrates that there were no significant variations in the plasma levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine among the treatment and control groups for both sexes of the animals that consistently received oral doses of PBD at dosages of 5, 50, and 300 mg/kg over the 28-day study duration. The histopathological examination of the vital organs, including the kidneys, liver, lungs, and spleen, exhibited no consistent treatment-related macroscopic or histological alterations in either sex of the animals administered PBD (Fig 6). The histological sections of the liver displayed normal architecture, with hepatocytes organized around central veins, revealing no evidence of necrosis, lesions, or any pathological damage. Furthermore, the observation of histological sections of the kidneys from PBD-treated rats revealed adequate glomeruli and normal tubules, with no signs of glomerular damage or the presence of lumen casts. Lastly, no histopathological lesions related to the test article were identified in the spleen, which exhibited normal histology of the white pulp, red pulp, and central arterioles. 10.1371/journal.pone.0339571.t007Table 7Hematological parameters in male and female rats treated orally with doses of 5, 50, and 300 mg/kg/day of Phy-Blica-D extract during a 90-day repeated oral dose toxicity study.Parameters (unit)*ControlDose of Phy-Blica-D extract (mg/kg/day)550300 Male rats (n = 5) White blood cell count (103/mm3)3.76 ± 0.333.50 ± 0.923.93 ± 0.323.31 ± 0.82Lymphocytes (%)75.28 ± 8.5176.58 ± 3.2176.23 ± 6.6377.78 ± 6.29Monocytes (%)12.90 ± 1.9712.15 ± 2.7711.29 ± 3.1111.65 ± 3.94Granulocytes (%)13.05 ± 3.4413.90 ± 3.3714.15 ± 2.8214.33 ± 4.19Red blood cell count (106/mm3)8.78 ± 0.768.67 ± 0.348.83 ± 0.488.65 ± 0.32Hemoglobin (g/dL)14.64 ± 0.8914.68 ± 0.4114.90 ± 0.6914.94 ± 0.44Hematocrit (%)49.54 ± 0.7849.48 ± 1.3848.26 ± 1.9148.10 ± 1.46Mean corpuscular volume (fL)56.44 ± 0.9457.12 ± 1.1456.76 ± 1.9255.50 ± 1.56Mean corpuscular hemoglobin (pg)17.02 ± 0.5517.20 ± 0.6017.64 ± 0.4816.94 ± 0.62Red cell distribution width (%)13.70 ± 0.2713.48 ± 0.6713.52 ± 0.2613.56 ± 0.49Platelet count (103/mm3)640.20 ± 46.86664.00 ± 84.07693.40 ± 66.53667.33 ± 74.11 Female rats (n = 5) White blood cell count (103/mm3)1.66 ± 0.811.36 ± 0.391.96 ± 0.961.84 ± 0.95Lymphocytes (%)78.10 ± 10.7576.19 ± 6.8871.39 ± 8.3573.35 ± 8.42Monocytes (%)13.72 ± 2.3913.33 ± 3.4614.15 ± 5.4314.93 ± 5.16Granulocytes (%)11.35 ± 5.9012.30 ± 2.8013.68 ± 3.4511.55 ± 4.32Red blood cell count (106/mm3)8.07 ± 0.407.80 ± 0.288.05 ± 0.268.53 ± 0.26Hemoglobin (g/dL)15.10 ± 0.9414.54 ± 0.8714.66 ± 0.4015.21 ± 0.88Hematocrit (%)48.46 ± 2.3646.44 ± 1.1846.34 ± 1.9149.03 ± 2.46Mean corpuscular volume (fL)59.02 ± 2.8759.36 ± 1.3657.62 ± 2.1857.48 ± 2.26Mean corpuscular hemoglobin (pg)18.70 ± 0.3718.90 ± 0.4218.22 ± 0.6818.93 ± 0.51Red cell distribution width (%)12.34 ± 0.1712.18 ± 0.2912.28 ± 0.1912.40 ± 0.24Platelet count (103/mm3)743.60 ± 84.00791.60 ± 50.79713.40 ± 82.66804.25 ± 69.17Values are expressed as mean ± SD. * Within a row for each organ, indicates a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Hematological parameters in male and female rats treated orally with doses of 5, 50, and 300 mg/kg/day of Phy-Blica-D extract during a 90-day repeated oral dose toxicity study. Values are expressed as mean ± SD. * Within a row for each organ, indicates a significant difference (p < 0.05), based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Serum biochemical values of male and female rats were measured at the end of a 90-day repeated oral dose toxicity study of Phy-Blica-D extract. Values are presented as mean ± SD (n = 5). Key parameters include creatinine, ALP (alkaline phosphatase), BUN (blood urea nitrogen), and ALT (alanine aminotransferase). * Indicating a significant difference (p < 0.05) among the groups for each parameter, based on one-way ANOVA followed by Bonferroni’s post-hoc comparison tests. Photomicrographs of kidney (A-D), liver (E-H), spleen (I-L), and lung (M-P) sections stained with hematoxylin and eosin from a 90-day repeated oral dose toxicity study of Phy-Blica-D extract are displayed. Panels A, E, I, and M show normal histology of kidney, liver, spleen, and lung tissue, respectively, in control rats at the end of the study period. Panels B, F, J, and N depict tissue sections from rats treated with 5 mg/kg of Phy-Blica-D extract; C, G, K, and O with 50 mg/kg; and D, H, L, and P with 300 mg/kg. 4. Discussion Traditional polyherbal formulations are gaining considerable attention in functional foods due to their health-promoting properties, minimal side effects, and potential benefits in preventing age-related and chronic illnesses [24–26]. This study highlights the possibility of developing and optimizing a traditional polyherbal beverage, PBO, as a functional ingredient utilizing an advanced microencapsulation technique. Our findings indicated that encapsulation efficiency was significantly influenced by both drying temperature and the composition of encapsulation materials, specifically MD and GA. Optimal encapsulation efficiencies for the PBO and its phenolic-rich extracts were achieved at lower drying temperatures (140°C), with higher proportions of MD, consistent with previous research highlighting the effectiveness of maltodextrin in preserving bioactive components during drying processes [12–14,27–29]. This protective role is attributed to its low viscosity, high water solubility, and excellent film-forming ability, which contribute to forming a stable encapsulating matrix around heat-sensitive phytochemicals, thereby minimizing thermal degradation and oxidation during spray-drying [12,27–29]. Conversely, increased GA content led to lower encapsulation efficiencies, likely due to enhanced solution viscosity, which may impede effective drying, as observed in earlier studies [12–14]. Physicochemical analyses revealed that microcapsules produced at elevated drying temperatures had lower moisture contents and water activity levels, conditions favorable for enhancing product stability and prolonging shelf-life [29–31]. Such characteristics significantly reduce microbial contamination and chemical degradation, both critical for market acceptance and consumer safety. In addition, microcapsules containing high GA proportions, such as CE180_6:4, which showed the highest hygroscopicity (15.51% after 7 days), can lead to moisture uptake, particle caking, reduced flowability, and potential degradation of antioxidant potency during storage. These issues might impact shelf life and handling processes during manufacturing and distribution. Nevertheless, formulations with increased GA content exhibited elevated hygroscopicity, a characteristic previously associated with gum Arabic due to its high affinity for moisture and its molecular structure rich in hydrophilic polysaccharides. This property causes microcapsules containing higher GA proportions to absorb more atmospheric water during storage, potentially compromising their stability and shelf life. For example, Ahmadi et al. (2025) demonstrated that clove extract microcapsules containing higher ratios of GA showed significantly greater moisture uptake after 7 days compared to those encapsulated with maltodextrin alone [32]. Similarly, Akhavan Mahdavi et al. (2016) reported that gum Arabic increased water sorption and reduced flowability in anthocyanin powders [33]. These findings are consistent with our results, where microcapsules with a 6:4 MD:GA ratio (e.g., CE180_6:4) showed the highest hygroscopicity (15.51% after 7 days), reinforcing the need to optimize wall material composition to balance bioactive preservation and physical stability. Color characteristics were essential determinants of consumer acceptance, with higher MD ratios yielding lighter, aesthetically preferable powders. Conversely, higher GA proportions resulted in darker and yellower powders, negatively affecting consumer perceptions. These findings align with prior studies that emphasized consumer preference for lighter-colored herbal beverages [34,35]. Therefore, the use of maltodextrin alone or combined minimally with GA is advisable to ensure desirable visual attributes. The antioxidant activity assessments identified the microcapsule formulation CE180_6:4 as exhibiting superior performance across multiple assays (DPPH, ABTS, FRAP), suggesting effective preservation of phenolic antioxidants. The optimized GA proportions significantly contributed to the preservation of these antioxidants, aligning with prior research on the protective effects of GA against the thermal degradation of bioactive compounds [26,30,36]. Interestingly, crude extracts displayed consistently higher antioxidant potency than phenolic-rich fractions, as expected due to the lower content of core-coating material in the microcapsule powder of the phenolic-rich extracts compared to the microcapsule powder of the PBO decoction. Although CE140_6:4 achieved the highest TPC (102.05 mg GA/g extract), this did not correspond to the strongest antioxidant activity. In contrast, CE180_6:4 consistently showed better antioxidant results in DPPH, ABTS, and FRAP tests, even with a slightly lower TPC. This indicates that antioxidant effectiveness relies not only on phenolic content but also on the stability and retention of bioactive compounds during spray drying. The higher inlet temperature of 180°C appears to help preserve the bioactivity of phenolics in the CE180_6:4 formulation. Furthermore, this study also reveals sub-chronic toxicity information of a PBO-based tea blend, PBD. This repeated 90-day oral toxicity study is one of the studies employed in evaluating the safety of food ingredients, pharmaceuticals, and various chemical substances. In addition to the safety information obtained in this study, PBD is well-accepted by consumers, demonstrates significant in vitro antioxidant capacity, and shows no consistent treatment-related toxicological changes following repeated oral administrations over 28 days [9,10,15,16]. This should also be emphasized as a promising functional beverage. Phy-Blica-D comprises a combination of various medicinal herbs, including Phyllanthus emblica, Terminalia arjuna, Terminalia bellirica, Cyperus rotundus, Maerua siamensis, Tinospora crispa, Terminalia citrina, Allium sativum, Piper retrofractum, Zingiber officinale, Alpinia galangal, Glycyrrhiza glabra, Solanum torvum, and Aegle marmelos [15,16]. These selected herbs have demonstrated notable antioxidant properties, functioning as both primary and secondary antioxidants. Several herbs, such as P. emblica [37], T. arjuna [38], T. bellirica [39], T. crispa [40], A. sativum [41], and Z. officinale [42] are widely supported by animal and clinical studies for their beneficial biological effects, including antioxidant, glucose-lowering, lipid-lowering, anti-inflammatory, and liver-protective activities. Additionally, herbs like G. glabra [43] and A. marmelos [44], chosen for their taste-enhancing attributes, also exhibit established antioxidant activities and confirmed safety profiles. Our previous study has revealed several bioactive compounds, including 6-galloylglucose, ferulic acid, naringenin, glycyrrhizic acid, and 6-gingerol, found in PBD [16]. These components have been reported in vivo and in clinical studies for their remarkable antioxidant properties and other health benefits [45–47]. Therefore, these compounds are proposed as suitable biological markers contributing to the overall antioxidant efficacy of Phy-Blica-D. The findings from the ongoing sub-chronic toxicity assessment show that the No-Observed-Adverse-Effect Level (NOAEL) for the PBD decoction exceeds 300 mg/kg body weight per day, equating to roughly 3.7 L/kg body weight daily. No signs of organ-specific toxicity were detected in either male or female rats. The NOAEL of 300 mg/kg/day in rats corresponds to a human equivalent dose (HED) of 50.27 mg/kg/day based on standard conversion [48]. Given that the extract concentration in PBD was approximately 83.8 mg/100 mL (0.838 mg/mL), this HED equates to an approximate beverage intake of 600 mL/kg/day. As mentioned in our previous article, 12 of the 14 herbal components indicated LD50 values between 1,000 and 5,000 mg/kg body weight [16]. The Globally Harmonized System of Classification and Labelling of Chemicals (GHS) classifies 10 of the 14 herbs in PBD—specifically P. emblica, T. arjuna, T. bellirica, C. rotundus, T. crispa, T. citrina, A. sativum, Z. officinale, A. galanga, and S. torvum—into category 5, signifying relatively low acute toxicity with LD50 values over 2,000 mg/kg body weight and up to 5,000 mg/kg [16]. Therefore, the current results reinforce the safety of the PBD formulation, establishing an essential scientific basis for determining dosing parameters for future in vivo studies, which will include assessments of its hypoglycemic, hypolipidemic, and antioxidant effects on non-communicable diseases. PBO and PBD are recognized as traditional herbal tonics that warrant further investigation to emphasize their potential biological activity and safety as functional ingredients or beverage products. Although this study provides extensive evidence on the antioxidant potential, physicochemical properties, and sub-chronic toxicity profile of the developed polyherbal functional beverage, some limitations remain. The existing safety assessment primarily relied on animal models, specifically rats. Consequently, the findings, especially those related to toxicity and dosing advice, require validation through future clinical studies involving human participants. Furthermore, this study did not thoroughly evaluate the long-term stability of the encapsulated herbal powder under actual commercial storage conditions, which is crucial for establishing practical shelf-life guidelines. Significantly, the increased hygroscopicity seen in CE180_6:4 (15.51% after 7 days) poses a storage challenge. To address this, future formulations might lower the GA proportion or add encapsulation stabilizers. Additionally, enhancing commercial viability could involve moisture-barrier packaging (such as aluminum foil laminates with desiccants) and cold-chain storage systems. 5. Conclusions This study successfully developed and optimized PBO into a functional ingredient using spray-drying microencapsulation. Optimal encapsulation efficiency was achieved at 140°C with maltodextrin as the wall material. At the same time, superior antioxidant activity was observed in formulations prepared at 180°C with a maltodextrin:gum Arabic ratio of 6:4. These encapsulated powders demonstrated favorable physicochemical properties, which may contribute to improving their stability and bioactivity. The resulting formulation, PBD, showed high consumer acceptability, potent in vitro antioxidant activity, and no observed adverse effects in a 90-day sub-chronic oral toxicity study, with a NOAEL exceeding 300 mg/kg/day. These results confirm the potential of PBD as a safe, antioxidant-rich functional beverage. For practical utilization, this research supports developing PBD as a commercially viable product within the functional food and complementary medicine industries. The encapsulated powder could be incorporated into ready-to-drink teas, dietary supplements, or wellness formulations targeting oxidative stress-related health concerns. However, further evaluation of the long-term storage stability of microencapsulated powders under real-world conditions, along with the bioavailability and pharmacokinetics of the key bioactive compounds in vivo, is necessary for manufacturing and application. Supporting information Composition of Phyllanthus emblica-based functional herbal tea with varying proportions of herbs and spices (grams of each plant per 2.5 g). (DOCX) Sensory data for functional herbal tea based on Phyllanthus emblica with varying proportions of herbs and spices. (DOCX) The particle size distribution profiles of microencapsulated Phy-Blica-O powders, prepared by spray drying at various inlet temperatures (140°C: panels A–C; 180°C: panels D–F) and different maltodextrin (MD) to gum Arabic (GA) ratios: (A, D) MD:GA (10:0), (B, E) MD:GA (8:2), and (C, F) MD:GA (6:4) are presented. Particle sizes are displayed as differential volume (%) and cumulative volume (%) distribution curves. (DOCX) The particle size distribution profiles of microencapsulated polyphenol-rich extracts from Phy-Blica-O powders were prepared by spray drying at various inlet temperatures (140°C: panels A–C; 180°C: panels D–F) and different maltodextrin (MD) to gum Arabic (GA) ratios: (A, D) MD:GA (10:0), (B, E) MD:GA (8:2), and (C, F) MD:GA (6:4). Particle sizes are displayed as differential volume (%) and cumulative volume (%) distribution curves. (DOCX) The antioxidant activity of Phy-Blica herbal tea formulations is assessed by the inhibition of fluorescence decay in fluorescein. Fluorescence decay curves illustrate the relative fluorescence intensity (%) over 90 minutes in the presence of various sample concentrations (µg/mL): (A) Trolox (reference antioxidant), (B) Phy-Blica-O, (C) Phy-Blica-B, (D) Phy-Blica-D, and (E) Phy-Blica-E. A more significant inhibition of fluorescence decay indicates more potent antioxidant activity. (DOCX) 30 May 2025 Dear Dr. Chusri, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 14 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Shengqian Sun Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering. 3. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. 4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 5. Thank you for stating the following financial disclosure: This research was supported by the Prince of Songkla University (Pattani campus) (Grant No. SAT601363S) and was partially supported by Mae Fah Luang University (Grant No. 651C5003). Mae Fah Luang University covered the article processing fees charge. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 6. Thank you for stating the following in the Acknowledgments Section of your manuscript: This research was supported by the Prince of Songkla University (Pattani campus) (Grant No. SAT601363S) and was partially supported by Mae Fah Luang University (Grant No. 651C5003). Mae Fah Luang University covered the article processing fees charge. We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: This research was supported by the Prince of Songkla University (Pattani campus) (Grant No. SAT601363S) and was partially supported by Mae Fah Luang University (Grant No. 651C5003). Mae Fah Luang University covered the article processing fees charge. Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: PLOS ONE Functional beverage development from traditional polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment General comment: The manuscript in reference compiles the reported “Functional beverage development from traditional polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment”. The manuscript has relevant information and organization that will be interesting for readers. However, some points need to be addressed before further consideration. 1. Abstract: The writing style should be concise, clear, and reflect the objectives, research methods, results, conclusions, and suggestions in full. 2. Introduction: -What are the highlights of this article? Should add details. 3. Method: -Should be shown a flow chart as an illustration of 2.1, 2.2, and 2.3. -Should be added details of equipment in this study, including model, brand, and country of manufacture. 4. Discussion: - “Optimal encapsulation efficiencies for the PBO and its phenolic-rich extracts were achieved at lower drying temperatures (140°C), with higher proportions of MD, consistent with previous research highlighting the effectiveness of maltodextrin in preserving bioactive components during drying processes [26-28].” Should be explained the role of maltodextrin in preserving bioactive components during the drying process. -“Nevertheless, formulations with increased GA content exhibited elevated hygroscopicity, a characteristic previously associated with GA, underscoring the necessity of selecting appropriate encapsulation materials [34, 35].” It should be clearly explained, including examples of related research and its relationship to the results obtained in this research. 5. Conclusion: -Should be rewritten and summarized important points that consistent with the article objectives -Should be added suggestions, utilization, and guidelines for future development. 6. Other Suggestions: -Should be checked the reference format according to the journal's requirements. -Should be updated references. Reviewer #2: The manuscript presents a comprehensive study on the development of a functional beverage, Phy-Blica-D (PBD), derived from a traditional Thai polyherbal tonic, Phy-Blica-O (PBO), through microencapsulation and sub-chronic toxicity assessment.However, the manuscript has some limitations, including incomplete statistical reporting, limited discussion of encapsulation trade-offs, and minor inconsistencies in terminology and data presentation. With revisions, the manuscript could make a significant contribution to the field of functional beverages and complementary medicine: 1. Title: Revise the short title to correct the grammatical error: “Phy-Blica-O and Phy-Blica-D: Development of Microcapsules and Sub-Chronic Toxicity Assessment.” Consider specifying “Thai” in the main title for clarity: “Functional Beverage Development from Traditional Thai Polyherbal Tonic...” Ensure keyword consistency (e.g., capitalize “Sub-Chronic Toxicity” to match others). 2. Abstract: Clarify the antioxidant activity claim by specifying which assays showed superiority for CE180_6:4 or acknowledge variability across assays. Correct or explain the HED calculation to ensure unit consistency (e.g., convert to volume based on beverage concentration). Specify the organs examined in the toxicity study for transparency. 3. Introduction: Streamline the functional food discussion to focus on herbal beverages and their specific benefits. Justify the choice of spray-drying by briefly comparing it to other encapsulation methods or citing its advantages (e.g., scalability, cost-effectiveness). Clarify the cytotoxicity findings (e.g., specify concentrations tested) to strengthen the safety claim. There is no explanation why encapsulation is important for PBO and PBD. There is no explanation why GA and MD were used for encapsulation of PBO and PBD. Please explain in details the gap in the research before the objectives. 4. Materials and methods: Justify the solvent choices and pH adjustments for phenolic extraction, citing relevant literature or preliminary experiments. Explain the selection of inlet temperatures (140°C, 180°C) based on prior studies or thermal stability of PBO components. What about the single treatment of MD or GA not in a combination. Clarify the statistical analysis for sensory data (e.g., ANOVA, significance level) and report results in a table or supplementary file. Include weekly body weight and food consumption trends in the toxicity study (e.g., as a supplementary figure) to show temporal patterns. 5. Results and discussion: Provide detailed statistical results (e.g., p-values, effect sizes) for antioxidant and toxicity data, and discuss significant comparisons in the text. Acknowledge the trade-off between TPC (higher in CE140_6:4) and other antioxidant assays (higher in CE180_6:4), and explain why CE180_6:4 was deemed optimal. Discuss potential solutions for high hygroscopicity (e.g., modified packaging, lower GA ratios) to enhance commercial viability. Include a table or figure summarizing sensory scores and panelist preferences to support claims about PBD’s consumer acceptability. Clarify the HED calculation, specifying the beverage concentration (e.g., mg/mL) and correcting the volume-based expression (mL/kg). 6. Conclusions: Balance the claim about CE180_6:4 by noting the TPC advantage of CE140_6:4 and clarifying the basis for optimality. Correct the HED expression and provide the beverage concentration used for the volume estimate. Expand the limitations to include stability testing and scalability challenges, with suggestions for future research. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Saeid Jafari ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. 6 Aug 2025 Reviewer #1: PLOS ONE Functional beverage development from traditional polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment” General comment: The manuscript in reference compiles the reported “Functional beverage development from traditional polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment”. The manuscript has relevant information and organization that will be interesting for readers. However, some points need to be addressed before further consideration. 1. Abstract: The writing style should be concise, clear, and reflect the objectives, research methods, results, conclusions, and suggestions in full. Author Response: We sincerely thank the reviewer for their valuable suggestion. In response, we have revised the abstract to clearly and concisely present the study’s objective, methodology, key findings, conclusion, and potential applications in the revised version. 2. Introduction: -What are the highlights of this article? Should add details. Author Response: Thank you for this insightful suggestion. We have revised the Introduction section to clearly highlight the main points and importance of the study. Specifically, we have (1) clarified the reason for transforming Phy-Blica-O (a traditional polyherbal tonic) into a functional ingredient through microencapsulation, (2) emphasized the novelty of combining optimization of spray-drying conditions with extensive physicochemical and antioxidant assessments, (3) highlighted the scientific and regulatory importance of conducting a 90-day sub-chronic oral toxicity study to ensure safety for human use, and (4) stressed the translational potential of PBD as a safe, antioxidant-rich functional beverage suitable for use in complementary and integrative medicine. 3. Method: -Should be shown a flow chart as an illustration of 2.1, 2.2, and 2.3. -Should be added details of equipment in this study, including model, brand, and country of manufacture. Author Response: We appreciate the reviewer for the helpful suggestion. In response, we have added a flow chart, now labeled as Figure 1, to visually illustrate the experimental workflow described in Sections 2.1 (Preparation of Phy-Blica-O herbal tea), 2.2 (Development of decoction and phenolic-rich extracts), and 2.3 (Microencapsulation via spray-drying). This illustration is intended to enhance reader comprehension of the stepwise procedures and clarify the overall methodology. Furthermore, we have thoroughly revised the Methods section to include the full specifications of all major equipment used in the study. This consists of the model number, brand name, and country of manufacture for equipment involved in freeze drying, spray-drying, particle analysis, microscopy, colorimetry, moisture, and water activity measurements. 4. Discussion: - “Optimal encapsulation efficiencies for the PBO and its phenolic-rich extracts were achieved at lower drying temperatures (140°C), with higher proportions of MD, consistent with previous research highlighting the effectiveness of maltodextrin in preserving bioactive components during drying processes [26-28].” Should be explained the role of maltodextrin in preserving bioactive components during the drying process. Author Response: We thank the reviewer for this helpful suggestion. In response, we have expanded the relevant sentence in the Discussion section to clarify the mechanistic role of maltodextrin (MD) in preserving bioactive compounds during spray-drying as follows. “Optimal encapsulation efficiencies for the PBO and its phenolic-rich extracts were achieved at lower drying temperatures (140°C), with higher proportions of MD, consistent with previous research highlighting the effectiveness of maltodextrin in preserving bioactive components during drying processes [26-28]. This protective role is attributed to its low viscosity, high water solubility, and excellent film-forming ability, which contribute to forming a stable encapsulating matrix around heat-sensitive phytochemicals, thereby minimizing thermal degradation and oxidation during spray-drying [26–28].” -“Nevertheless, formulations with increased GA content exhibited elevated hygroscopicity, a characteristic previously associated with GA, underscoring the necessity of selecting appropriate encapsulation materials [34, 35].” It should be clearly explained, including examples of related research and its relationship to the results obtained in this research. Author Response: We appreciate the reviewer’s insightful suggestion. In response, we have revised the discussion to explain the hygroscopic properties of gum Arabic better, supported by literature and linked to our findings as follows. “Nevertheless, formulations with increased GA content exhibited elevated hygroscopicity, a characteristic previously associated with gum Arabic due to its high affinity for moisture and its molecular structure rich in hydrophilic polysaccharides. This property causes microcapsules containing higher GA proportions to absorb more atmospheric water during storage, potentially compromising their stability and shelf life. For example, Ahmadi et al. (2025) demonstrated that clove extract microcapsules containing higher ratios of GA showed significantly greater moisture uptake after 7 days compared to those encapsulated with maltodextrin alone [34]. Similarly, Akhavan Mahdavi et al. (2016) reported that gum Arabic increased water sorption and reduced flowability in anthocyanin powders [35]. These findings are consistent with our results, where microcapsules with a 6:4 MD:GA ratio (e.g., CE180_6:4) showed the highest hygroscopicity (15.51% after 7 days), reinforcing the need to optimize wall material composition to balance bioactive preservation and physical stability.” 5. Conclusion: -Should be rewritten and summarized important points that consistent with the article objectives -Should be added suggestions, utilization, and guidelines for future development. Author Response: We thank the reviewer for this valuable recommendation. In response, we have revised the Conclusion section to better reflect the core objectives of the study, which are (i) optimizing microencapsulation of Phy-Blica-O (PBO) and (ii) evaluating the antioxidant capacity and sub-chronic toxicity of Phy-Blica-D (PBD), as well as incorporating recommendations for future research, potential applications, and product development guidelines as follows. “This study successfully developed and optimized PBO into a functional ingredient using spray-drying microencapsulation. Optimal encapsulation efficiency was achieved at 140°C with maltodextrin as the wall material. At the same time, superior antioxidant activity was observed in formulations prepared at 180°C with a maltodextrin:gum Arabic ratio of 6:4. These encapsulated powders demonstrated favorable physicochemical properties, which may contribute to improve their stability and bioactivity. The resulting formulation, PBD, showed high consumer acceptability, potent in vitro antioxidant activity, and no observed adverse effects in a 90-day sub-chronic oral toxicity study, with a NOAEL exceeding 300 mg/kg/day. These results confirm the potential of PBD as a safe, antioxidant-rich functional beverage. For practical utilization, this research supports developing PBD as a commercially viable product within the functional food and complementary medicine industries. The encapsulated powder could be incorporated into ready-to-drink teas, dietary supplements, or wellness formulations targeting oxidative stress-related health concerns. However, further evaluation of the long-term storage stability of microencapsulated powders under real-world conditions, along with the bioavailability and pharmacokinetics of the key bioactive compounds in vivo, is necessary for manufacturing and application.” 6. Other Suggestions: -The reference should be checked according to the journal's requirements. -Should be updated references. Author Response: We sincerely thank the reviewer for this important comment. In response: - Reference Format: All references have been carefully reviewed and reformatted to fully comply with PLOS ONE's citation style, which follows the Vancouver style with the following structure: Author(s). Title. Journal Abbreviation. Year;Volume(Issue):Page range. doi (if available). - Updated References: We have updated and replaced outdated or superseded citations with more recent publications (mostly from the past 5 years). This ensures the manuscript reflects the current state of research in functional food development, microencapsulation, and polyherbal safety assessment. - DOI Inclusion: Where applicable, DOIs have been added to all journal articles, in accordance with PLOS ONE’s submission guidelines. We believe these adjustments improve both the academic rigor and alignment with the journal’s formatting standards. Reviewer #2: The manuscript presents a comprehensive study on the development of a functional beverage, Phy-Blica-D (PBD), derived from a traditional Thai polyherbal tonic, Phy-Blica-O (PBO), through microencapsulation and sub-chronic toxicity assessment. However, the manuscript has some limitations, including incomplete statistical reporting, limited discussion of encapsulation trade-offs, and minor inconsistencies in terminology and data presentation. With revisions, the manuscript could make a significant contribution to the field of functional beverages and complementary medicine: 1. Title: Revise the short title to correct the grammatical error: “Phy-Blica-O and Phy-Blica-D: Development of Microcapsules and Sub-Chronic Toxicity Assessment.” Consider specifying “Thai” in the main title for clarity: “Functional Beverage Development from Traditional Thai Polyherbal Tonic...” Ensure keyword consistency (e.g., capitalize “Sub-Chronic Toxicity” to match others). Author Response: We appreciate the reviewer’s detailed and helpful suggestions. For the Short Title, we have revised it to correct the grammatical error and improve clarity and conciseness. The original “Phy-Blica-O and Phy-Blica-D: Development of Microcapsules and Sub-Chronic Toxicity Assessment” has been updated to "Development of Microcapsules and Sub-Chronic Toxicity of Phy-Blica Formulations." Furthermore, we agree with the suggestion to clarify the geographic and traditional context by specifying "Thai" in the main title. Therefore, the main title was changed from ‘Functional Beverage Development from Traditional Polyherbal Tonic: Antioxidant-Rich Microcapsules and Comprehensive Sub-Chronic Toxicity Assessment’ to ‘Functional Beverage Development from Traditional Thai Polyherbal Tonic: Antioxidant-Rich Microcapsules and Comprehensive Sub-Chronic Toxicity Assessment’ We have ensured consistency by capitalizing "Sub-Chronic Toxicity" to align with the formatting of other keywords. We believe these revisions enhance the clarity, specificity, and consistency of the manuscript presentation and are now fully aligned with journal expectations. 2. Abstract: Clarify the antioxidant activity claim by specifying which assays showed superiority for CE180_6:4 or acknowledge variability across assays. Correct or explain the HED calculation to ensure unit consistency (e.g., convert to volume based on beverage concentration). Specify the organs examined in the toxicity study for transparency. Author Response: We sincerely thank the reviewer for this thoughtful and constructive feedback. In response, we have revised the Abstract to address all points raised: - Antioxidant Activity of CE180_6:4: We have clarified that the CE180_6:4 microcapsule formulation showed superior antioxidant activity based on specific in vitro assays. The revised sentence now states:“Maximum encapsulation efficiency was achieved at 140°C with MD-only wall materials, while microcapsules with a 6:4 MD:GA ratio at 180°C exhibited the highest antioxidant activity based on DPPH, ABTS, and FRAP assays.” This provides clear attribution of assay-specific performance rather than implying universal superiority. - Human Equivalent Dose (HED): To ensure unit consistency, we have clarified how the HED was derived from the NOAEL and converted to an approximate beverage volume based on the concentration used in the study. The revised sentence reads: “The calculated human equivalent dose is 50.27 mg/kg/day, which corresponds to an estimated volume of approximately 600 mL/kg/day based on the extraction yield obtained from the beverage.” - Organs Examined in Toxicity Study: We have added detail on the organs examined for histopathological analysis to improve transparency. The sentence now reads: “The oral no-observed-adverse-effect level (NOAEL) exceeded 300 mg/kg/day, with normal histopathological profiles in the liver, kidneys, and spleen.” 3. Introduction: Streamline the functional food discussion to focus on herbal beverages and their specific benefits. Justify the choice of spray-drying by briefly comparing it to other encapsulation methods or citing its advantages (e.g., scalability, cost-effectiveness). Clarify the cytotoxicity findings (e.g., specify concentrations tested) to strengthen the safety claim. There is no explanation why encapsulation is important for PBO and PBD. There is no explanation why GA and MD were used for encapsulation of PBO and PBD. Please explain in details the gap in the research before the objectives. Author Response: We thank the reviewer for these insightful comments. In response, we have carefully revised the Introduction section to address each point and strengthen the scientific rationale of the study. The following amendments have been made: - Streamlining the functional food discussion: We revised the beginning of the introduction to specifically highlight herbal beverages as a subgroup of functional foods. The updated paragraph emphasizes their contribution to health, antioxidant properties, and traditional uses, rather than broadly discussing all types of functional foods. - Justification for spray-drying: We have now included a brief comparison of encapsulation methods and provided the rationale for using spray-drying, with relevant citations added to support this justification. - Clarification of cytotoxicity findings: We have expanded the discussion of our previous cytotoxicity work by stating ‘Among these formulas, Phyllanthus emblica-based functional herbal tea (THP-R016 or Phy-Blica-O (PBO)) possessed notable antioxidant properties and did not exhibit cytotoxic effects on Vero cells at concentrations up to 100 µg/mL, supporting its safety for oral applications [12, 13].’ - Importance of encapsulation for PBO and PBD: We have added a paragraph to explain why encapsulation is critical, stating that: ‘The utilization of microencapsulation in PBO not only enhances the sensory profile but also protects heat-sensitive bioactive compounds from degradation, thereby improving the functional properties and shelf-life of the formulation [14].’ - Rationale for using gum Arabic (GA) and maltodextrin (MD): We have now provided a detailed rationale, as follows. ‘Additionally, maltodextrin (MD) and gum Arabic (GA) are common wall materials in spray-drying botanical extracts because of their excellent film-forming, emulsifying, and protective qualities [15-17]. MD helps achieve high encapsulation efficiency and maintains low viscosity, whereas GA improves stability and retains antioxidants. Using them together has been demonstrated to increase encapsulation yields and functional performance in earlier research [15–17].’ 4. Materials and methods: Justify the solvent choices and pH adjustments for phenolic extraction, citing relevant literature or preliminary experiments. Explain the selection of inlet temperatures (140°C, 180°C) based on prior studies or thermal stability of PBO components. What about the single treatment of MD or GA not in a combination. Clarify the statistical analysis for sensory data (e.g., ANOVA, significance level) and report results in a table or supplementary file. Include weekly body weight and food consumption trends in the toxicity study (e.g., as a supplementary figure) to show temporal patterns. Author Response: We appreciate the reviewer’s detailed and Submitted filename: Respond to reviewer (point-by-point) Revised_(PBO and PBD).docx 26 Aug 2025 Dear Dr. Chusri, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 10 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Shengqian Sun Academic Editor PLOS ONE Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: This article has been edited based on feedback. This article is suitable for publication in PLOS ONE. Reviewer #2: Major Comments Statistical Reporting – While p-values and comparisons are included, effect sizes and confidence intervals should be more explicitly presented to strengthen result interpretation. Encapsulation Trade-offs – The discussion should better highlight the balance between high TPC (CE140_6:4) and superior antioxidant activity (CE180_6:4), clarifying the rationale for selecting the “optimal” formulation. Hygroscopicity Limitation – The practical challenges of high GA content (storage instability) should be more explicitly connected to commercial implications and possible solutions. Toxicity Study Reporting – Weekly body weight and food intake trends are added, but a brief summary of variability and overall trajectory in the main text would enhance clarity. Minor Comments Abstract: Slightly long—could be streamlined for clarity, focusing on objective, key findings, and implications. Introduction: Nicely revised, though still somewhat broad. Consider reducing general functional food market data and focusing more directly on herbal beverages. Figures/Tables: Supplementary figures and tables are well presented. Ensure that all abbreviations are defined at first mention. References: Updated references are appropriate, but a few older citations remain; consider substituting with more recent (past 5 years) where possible. Language: Overall clear, but some sentences could be shortened to improve readability ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Saeid Jafari ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org 30 Nov 2025 Dear Editors, On behalf of my co-authors, I am pleased to resubmit our revised manuscript titled: “Functional Beverage Development from Traditional Thai Polyherbal Tonic: Antioxidant-Rich Microcapsules and Comprehensive Sub-Chronic Toxicity Assessment” (Manuscript ID: PONE-D-25-18265R2) for reconsideration for publication in PLOS ONE. We would like to express our sincere gratitude to the editorial team and reviewers for their thoughtful and constructive feedback. We have thoroughly addressed all comments and suggestions in the revised manuscript and the accompanying point-by-point response document, as listed at the end of the cover letter. We believe that the revised version significantly improves the clarity, methodological transparency, and scientific rigor of our work, aligning with PLOS ONE’s editorial standards and scope. I appreciate your consideration and look forward to your favorable response. Best Regards, Sasitorn Chusri, Ph.D. Corresponding Author Biomedical Technology Research Group for Vulnerable Populations, School of Health Science, Mae Fah Luang University Muang, Chiang Rai 57100, Thailand E-mail: sasitorn.chu@mfu.ac.th Reviewer #2: Major Comments 1. Statistical Reporting – While p-values and comparisons are included, effect sizes and confidence intervals should be more explicitly presented to strengthen result interpretation. Address to the reviewer’s comment: We thank you for this helpful suggestion. In response, we've revised the Results section to explicitly report effect sizes with 95% confidence intervals where relevant. These updates help readers understand both the magnitude and precision of the effects, going beyond just p-values. Additionally, we've updated tables to show effect sizes alongside statistical results. 2. Encapsulation Trade-offs – The discussion should better highlight the balance between high TPC (CE140_6:4) and superior antioxidant activity (CE180_6:4), clarifying the rationale for selecting the “optimal” formulation. Address to the reviewer’s comment: Thank you for this insightful comment. We appreciate the reviewer’s suggestion to more clearly explain the trade-offs between total phenolic content (TPC) and antioxidant activity and to clarify the rationale behind selecting the optimal formulation. In response, we have revised the Results and Discussion to explain how these factors influenced the formulation choice explicitly. Specifically, we now note that although CE140_6:4 showed the highest TPC (102.05 mg GA/g extract), this did not necessarily indicate the best antioxidant performance. Instead, microcapsules produced at 180°C with a 6:4 MD:GA ratio (CE180_6:4) consistently exhibited stronger antioxidant activity in DPPH, ABTS, and FRAP assays, indicating better retention and stability of key bioactive compounds at higher drying temperatures. This suggests that antioxidant strength depends not only on the amount of phenolics but also on their chemical stability after encapsulation. This information was added to the results and discussion sections. 3. Hygroscopicity Limitation – The practical challenges of high GA content (storage instability) should be more explicitly connected to commercial implications and possible solutions. Address to the reviewer’s comment: Thank you for your insightful comment. We agree that the practical impact of high hygroscopicity in GA-rich formulations should be more clearly linked to commercial considerations and potential mitigation strategies. Therefore, we expanded the discussion to emphasize how high GA levels, especially in formulations like CE180_6:4, which had the highest hygroscopicity (15.51% after 7 days), present real challenges for product stability during storage, handling, and distribution. The updated text now underscores that excessive moisture uptake can lead to particle caking, decreased flowability, reduced antioxidant effectiveness, and shorter shelf life, which are key factors for the commercial application of microencapsulated herbal ingredients. These modifications enhance the Discussion section by clearly connecting scientific results to practical formulation challenges and industry solutions. To address these challenges, we included clearer solutions such as (1) decreasing GA content or adjusting MD: GA ratios to balance phenolic protection and physical stability (2) incorporating stabilizing co-encapsulants (3) using moisture-barrier packaging methods (e.g., aluminum foil laminates, desiccants, low-permeability films). 4. Toxicity Study Reporting – Weekly body weight and food intake trends are added, but a brief summary of variability and overall trajectory in the main text would enhance clarity. Address to the reviewer’s comment: Thank you for your helpful comment. We agree that summarizing the weekly body weight and food-intake trends in the main text would enhance clarity and readability. Therefore, we have expanded the toxicity Results section to include a brief narrative that emphasizes the overall variability and trajectory observed over the 90-day study. The revised text now indicates that both male and female rats in all treatment groups experienced consistent, gradual increases in body weight over 90 days, without any abnormal fluctuations or deviations from the control group. Weekly food intake patterns remained stable and similar across all groups, with only minor weekly variations typical of normal physiological cycles. Notably, no dose-dependent effects were observed in either parameter, reinforcing the absence of treatment-related toxicity. This summary improves the clarity of the weekly data while remaining aligned with the detailed figures provided. Minor Comments 5. Abstract: Slightly long—could be streamlined for clarity, focusing on objective, key findings, and implications. Address to the reviewer’s comment: Thank you for this constructive comment. We appreciate the suggestion to make the abstract clearer and more focused. In response, we have revised the abstract to be more concise, highlighting the study’s main goal, the key findings from microencapsulation optimization and toxicity testing, and the main implications for developing functional beverages. 6. Introduction: Nicely revised, though still somewhat broad. Consider reducing general functional food market data and focusing more directly on herbal beverages. Address to the reviewer’s comment: Thank you for the insightful comment. We agree that the Introduction section would benefit from a tighter focus on herbal beverages rather than a broader discussion of the functional food market. We removed several sentences and citations related to overall trends in the functional food market. This revision offers a clearer context for the study by directly linking PBO and its microencapsulation to current research and development in herbal-based functional drinks. 7. Figures/Tables: Supplementary figures and tables are well presented. Ensure that all abbreviations are defined at first mention. Address to the reviewer’s comment: Thank you for your positive feedback on the supplementary figures and tables. We appreciate the reviewer’s reminder regarding the clarity of abbreviations. In response, we reviewed the entire manuscript, including the supplementary figures, tables, and captions, to ensure that all abbreviations are defined at first use, covering methodological terms, assays, sample codes, and parameters. These updates improve clarity and consistency. 8. References: Updated references are appropriate, but a few older citations remain; consider substituting with more recent (past 5 years) where possible. Address to the reviewer’s comment: Thank you for highlighting the importance of the updated references. We reviewed the reference list and replaced many older citations with recent studies (from the past 5 years), especially in areas like functional herbal beverages, microencapsulation, and antioxidant assessment. We retained a few older references that are still seminal or foundational for traditional Thai polyherbal formulations and microencapsulation methodology, where no recent alternatives exist. This blend of updated and classic references offers a current yet historically grounded context for the work. 9. Language: Overall clear, but some sentences could be shortened to improve readability. Address to the reviewer’s comment: Thank you for this helpful comment. We have carefully re-read the entire manuscript, focusing on sentence length and readability. In response, we shortened several long, multi‑clause sentences, especially in the Introduction, Discussion, and Methods sections, and removed minor redundancies to improve flow without changing the scientific meaning. Submitted filename: (PBO and PBD)_Reponse to reviewer.docx 9 Dec 2025 Functional beverage development from traditional Thai polyherbal tonic: Antioxidant-rich microcapsules and comprehensive sub-chronic toxicity assessment PONE-D-25-18265R2 Dear Dr. Chusri, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Shengqian Sun Academic Editor PLOS One Additional Editor Comments (optional): Although the manuscript is suitable for acceptance, one of the reviewers has still provided some comments, and we hope you could further polish the manuscript according to these suggestions to enhance its quality. Reviewers' comments: Statistical Reporting – While p-values and comparisons are included, effect sizes and confidence intervals should be more explicitly presented to strengthen result interpretation. Encapsulation Trade-offs – The discussion should better highlight the balance between high TPC (CE140_6:4) and superior antioxidant activity (CE180_6:4), clarifying the rationale for selecting the “optimal” formulation. Hygroscopicity Limitation – The practical challenges of high GA content (storage instability) should be more explicitly connected to commercial implications and possible solutions. Toxicity Study Reporting – Weekly body weight and food intake trends are added, but a brief summary of variability and overall trajectory in the main text would enhance clarity. Minor Comments Abstract: Slightly long—could be streamlined for clarity, focusing on objective, key findings, and implications. Introduction: Nicely revised, though still somewhat broad. Consider reducing general functional food market data and focusing more directly on herbal beverages. Figures/Tables: Supplementary figures and tables are well presented. Ensure that all abbreviations are defined at first mention. References: Updated references are appropriate, but a few older citations remain; consider substituting with more recent (past 5 years) where possible. Language: Overall clear, but some sentences could be shortened to improve readability PONE-D-25-18265R2 PLOS One Dear Dr. Chusri, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Shengqian Sun Academic Editor PLOS One